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linical Research
esigns and Implantable
efibrillator Indications
pend in the
eginning or Pay at the End*
obert J. Myerburg, MD, FACC,
gustin Castellanos, MD, FACC
iami, Florida
he evolution of scientific evidence supporting the benefit
f implantable cardioverter defibrillators (ICDs) began with
16-year hiatus between the first clinical implant in 1980
nd the publication of the first randomized clinical trial
RCT) results in December 1996 (1). During that interval,
mportant perceptions developed from a combination of
ase-control studies, observational data, and expert consen-
us. Although these sources lacked the scientific authority of
CTs, they were sufficient to achieve U.S. Food and Drug
dministration approval for ICDs by 1985, and in 1986
edicare approved funding for patients surviving cardiac
rrest or experiencing life-threatening arrhythmias. Calcu-
ations based on numbers of implants and the cost of devices
uggest that the ICD industry approached sales of $1 billion
er year by the time the first RCT was published.
See page 98
Since December 1996, the results of a substantial series of
CTs have been published, targeted to both secondary and
rimary prevention strategies. During most of that time
nterval, the major debates have centered around the pri-
ary prevention strategies, given the large numbers of
otential candidates and the consequent impact on health
are costs. After the earlier of these studies, Medicare, and
ubsequently the Center for Medicare and Medicaid Ser-
ices (CMS), took a rather restrictive policy position for
pproval of device implants, but after publication of the
esults of the Sudden Cardiac Death-Heart Failure Trial
SCD-HeFT) (2), CMS proposed a much more permissive
osture (3). The potential impact of that decision on health
are costs may be as high as $10 to $15 billion according to
MS estimates (3). With figures of this magnitude in play,
gainst the backdrop of a fiscally stressed health care system,
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily reflect the views of JACC or the American
ollege of Cardiology.
From the Division of Cardiology, University of Miami Miller School of Medicine,
iami, Florida. Dr. Myerburg is supported in part by the American Heartb
ssociation Chair in Cardiovascular Research and the Cardiovascular Genetics
enter funded by the Miami Heart Research Institute.t behooves clinicians, clinical investigators, and health
ervices administrators to clarify the potential for benefit
ithin the broad groups of ICD candidates.
LINICAL TRIAL DESIGNS
he earliest among the primary prevention clinical trials had
ery rigorous entry criteria. The Multicenter Automatic
efibrillator Implantation Trial (MADIT) required four
linical features for entry into the study: an ejection fraction
EF) 35%, ambient arrhythmias after a myocardial infarc-
ion, inducibility of a sustained arrhythmia in the electro-
hysiology laboratory, and failure to suppress inducibility by
n antiarrhythmic drug (4). The Multicenter UnSustained
achycardia Trial (MUSTT), which had similar qualifying
equirements, was designed to determine the value of
ntiarrhythmic strategies for patients with ambient arrhyth-
ias and inducible arrhythmias, and a low EF after myo-
ardial infarction (5). One of the antiarrhythmic treatment
ptions in the complex algorithm was ICD implantation.
he ICD group fared better by far than antiarrhythmic
rug-treated subjects and untreated control patients, and
USTT was accepted as further support for ICD benefit
ven though ICD therapy was not randomized.
In contrast to the initial studies, MADIT II did not
equire ambient arrhythmias or electrophysiological induc-
bility, simply an EF 30% after a recent myocardial
nfarction (6). Another study, Defibrillators in Nonischemic
ardiomyopathy Treatment Evaluation (DEFINITE), in-
luded only patients with non-ischemic cardiomyopathy,
VCs or non-sustained VT, and an EF 35% (7). The
bsolute benefit, measured as reduction in total mortality,
as less in the MADIT II and DEFINITE studies than
bserved in the MADIT and MUSTT studies, which had
ore selective designs (Table 1). At first glance, this might
ot seem surprising, given the less stringent requirements
or entry into the MADIT II and DEFINITE studies, but
t is counterintuitive to the fact that the EFs of subjects
nrolled in the MADIT II and DEFINITE studies were
omewhat lower than the studies with greater frequencies of
utcome events (Table 2). This apparent paradox suggests
hat influences in study design that are additive to the power
f EF, but are yet to be identified, contributed significantly
o the net outcome experience.
LINICAL APPLICATION OF
HE MADIT II STUDY CRITERIA
lthough there has been no substantial debate about the
ADIT II study in regard to its fundamental design and
rimary end point outcome, there were debates about its
eneral applicability, particularly in regard to appropriate
linical applications of secondary subgroup analyses. These
ncluded the question of whether the observed clustering of
enefit in patients with wide QRS complexes was a valid
b
d
m
b
s
o
c
e
b
s
s
r
t
a
d
i
w
e
t
i
v
a
a
f
o
t
d
fi
s
e
c
b
i
h
s
g
I
h
T
s
s
a
t
o
T
a
(
a
T
S
P
A
c tricula
v
T
M
M
M
D
S
I
109JACC Vol. 47, No. 1, 2006 Myerburg and Castellanos
January 3, 2006:108–11 Editorial Commentasis for limiting device use in patients with normal QRS
urations, and whether electrophysiological inducibility
ight identify a subgroup that would achieve greater
enefit, compared with those without induced arrhythmias,
uch as suggested in the MUSTT data (8). With the advent
f data from the SCD-HeFT (2), designed for patients with
lass II or class III heart failure of ischemic or non-ischemic
tiology, and an EF 35%, the QRS duration issue faded,
ased in part on observations in that study and on CMS’s
ubsequent actions. Inducibility as a discriminating factor
till remained uncertain.
In this issue of the Journal, Daubert et al. (9) provide a
etrospective analysis of a subgroup of patients enrolled into
he MADIT II study who received ICDs after having had
n electrophysiological study before entry. The study design
id not permit the results of electrophysiological testing to
nfluence the randomization process, but one wonders
hether it influenced patient-physician discussions about
nrolling. Regardless, because a substantial proportion of
he MADIT II study enrollees who received ICDs did,
ndeed, undergo prior electrophysiological testing, the in-
estigators had a database sufficiently large to permit a valid
nalysis. The primary end point of this substudy was an
ppropriate ICD shock during follow-up, analyzed as a
unction of pre-implantation inducibility status. Definitions
able 1. Outcomes
Trial Study Group
econdary prevention studies
AVID VF, VT-syncope, VT-EF 40%
CIDS Cardiac arrest survivors (VF, VT)
CASH Cardiac arrest survivors (VF, VT)
rimary prevention studies
MADIT (2 yrs) Prior MI, EF 35%, N-S VT, inducible VT
failed intravenous PA
MUSTT (5 yrs) Prior MI, EF 40%, N-S VT, inducible VT
MADIT-2 (2 yrs) Prior MI, EF 30%
DEFINITE (2 yrs) Non-ischemic CM, EF 35%, PVCs, or N-
SCD-HeFT (5 yrs) Class II to III CHF, EF 35%
AD  antiarrhythmic drugs; CHF  congestive heart failure; CM  card
ardioverter-defibrillator; MI  myocardial infarction; N-S VT  non-sustained ven
entricular fibrillation; VT  ventricular tachycardia.
able 2. Primary Prevention Studies
Trial
Ejection Fraction (%)
Entry Criterion Actually Enrolled
ADIT 35 26 (SD  7)
USTT 40 30 (21, 35)
median (25th, 75th perce
ADIT-2 30 23 (SD  5)
EFINITE 35 21 (range, 7–35)
CD-HeFT 35 25 (20, 30)
median (25th, 75th perceCD  implantable cardioverter-defibrillator; SD  standard deviation.f induced arrhythmias included monomorphic ventricular
achycardia (MonoVT), polymorphic ventricular tachycar-
ia (PolyVT) and ventricular fibrillation (VF).
The investigators carried out three parallel analyses de-
ned by arbitrary definitions of induced arrhythmias. The
tandard definition was MonoVT or PolyVT induced by3
xtrastimuli, or VF induced by 2 extrastimuli. This was
ompared with a narrow definition of MonoVT only, and a
road definition that allowed MonoVT, PolyVT, or VF
nduced by 3 extrastimuli. The narrow definition group
ad a higher likelihood of ICD discharges than those in the
tandard definition group. Those in the broad definition
roup had a weaker association than the standard group.
nterestingly, patients inducible into MonoVT or PolyVT
ad a lower mortality rate than non-inducible patients.
herefore, the study suggests that inducibility into more
table arrhythmias (MonoVT) predicts the occurrence of
pontaneous stable arrhythmias, but that it does not provide
marker for mortality compared with non-inducible pa-
ients. The study also supports the notion that inducibility
f VF, particularly with aggressive protocols, is non-specific.
his is in contrast to the MUSTT substudy, which showed
n increased risk of all-cause mortality in inducible patients
8), and that inducibility predicted a higher likelihood that
subsequent death would be by an arrhythmic mechanism.
Control
(%)
ICDs
(%)
Relative Risk
Reduction (%)
Absolute Risk
Reduction (%)
25 18 27 7
21 15 30 6
20 12 37 8
(Combined control
arms)
32 13 59 19
55 24 58 31
(EP guided arm: AAD vs. ICD, 60 m)
22 16 28 6
14 8 35 6
36 29 23 7
pathy; EF  ejection fraction; EP  electrophysiology; ICD  implantable
r tachycardia; PA  procainamide; PVC  premature ventricular contraction; VF 
Appropriate ICD Shocks
Absolute Risk
Reduction (%)Patients (%) Annualized (%)
60 30 19
55 37 31
35 12 6
21 5.1 7
18 7.3 6,
S VT
iomyontile)
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Editorial Comment January 3, 2006:108–11This retrospective analysis from the MADIT II study
oes not provide data supporting the notion that inducibil-
ty in an electrophysiology laboratory will differentiate those
atients within the general MADIT II study criteria who
ould benefit from ICD implantation. However, the pri-
ary end point in the MADIT II study, and the basis for
CD use derived from the study, was a mortality benefit,
nd the design of this subgroup analysis was not intended to
ddress the mortality issue as a primary end point. Thus, the
uestion of identification of a higher mortality risk subgroup
emains unanswered. Nonetheless, it remains a pressing
uestion. If the estimates from CMS and other sources are
orrect, identification of subgroups within a substantially
arge population of potential candidates is both clinically
nd economically relevant.
RACTICAL VERSUS OPTIMAL STUDY DESIGNS
t is useful to look at the MADIT II study and this substudy
s part of the universe of trials addressing primary mortality
enefit. Unfortunately, interpretation of the entire series of
linical trials for ICD implantation, particularly among the
rimary prevention strategies, is hampered by design fea-
ures that permit broad general conclusions, but limited
pecific insights. An example is the pattern of EF observa-
ions in each of the clinical trials. There is no trial in which
Fs were stratified in an attempt to derive valid scientific
nswers to the question of whether varying levels of EFs
orrelate with the magnitude of clinical benefit. Table 2 lists
series of primary prevention trials and shows that the
pper limit of EF ranged from 30% and 40% among the
arious studies, with all but two set at 35%. The mean or
edian EF values were considerably below those upper
imits. Averaging down from an upper limit is a mathemat-
cal expectation when entry is so defined, but the magnitude
f the deviation in these studies is striking. This pattern is
elevant because once the results of a trial are accepted into
linical practice, it is the entry criterion and not the group
ctually studied that has driven practice guidelines. For each
f the trials, it is likely that stratifying EFs into at least two
r three ranges would have provided far more specific
nformation on the applicability of the conclusions derived
rom these studies than is achievable from more general
utcome figures. A hint about this dilemma was seen in a
roup analysis of the Antiarrhythmics Versus Implantable
efibrillators (AVID) study (a secondary prevention trial),
uggesting that individuals who survive cardiac arrest and
ave EFs 35% fared no better with an ICD than with
miodarone (10). As a retrospective subgroup analysis, this
bservation is hypothesis-generating rather than outcome-
efining and has not had any impact on ICD guidelines;
nly a prospective study could define that interpretation. It
ould be correctly argued that stratification of the primary
revention trials into multiple tiers of EF would have been
ar more costly and taken longer to complete. However,
iewed from the perspective of cost to society continuously wver time for indications that may or may not be valid,
ccurate insights into the outcomes of clinical trials have a
ar more enduring fiscal impact than a one-time increment
n cost of a major research project.
HERE DO WE GO FROM HERE?
here are two mathematical constructs that are relevant
o the interpretation of any clinical trial, including the
ADIT II study:
he benefit of a therapy based on relative (population
domain) and absolute (individual domain) improve-
ments in outcome
he efficiency of a therapy based on the proportion of
treated patients who will have an event for which the
therapy is intended
In regard to the more general primary prevention ICD
tudy designs (e.g., MADIT II, SCD-HeFT), the relative
nd absolute risk reductions are in acceptable ranges, but
ppropriate use rates raise concern about their efficiency.
he cumulative fraction of ICD-treated patients who ex-
erience appropriate shocks ranged from 5% to 12% per year
range, 21% over 5 years in the SCD-HeFT study to 35%
ver 3 years in the MADIT II study). Thus, the majority of
CD recipients for primary prevention indications, using the
ADIT II, DEFINITE, and SCD-HeFT study indica-
ions, did not experience appropriate shocks during the
ourse of those studies. This observation identifies the need
or strategies that can identify subgroups within the general
arget population that provide better predictive accuracy.
Despite this need, it will be difficult to perform additional
linical trials to fine-tune the efficacy and efficiency of
rimary prevention ICD strategies. Accordingly, CMS has
andated that, concomitant with more relaxed approval
riteria, post hoc registry data for ICDs can be used to
dentify segments of the more general population recently
pproved who may not achieve benefit, and therefore
alidate a future modification of approved implantation
riteria. This is an ambitious chore, but one that is not likely
o lead to a scientifically acceptable data set used to make
ecisions of this importance. Effective enforcement of this
andate remains uncertain. Control of data quality, thor-
ughness of data subsets, and selection biases are all factors
hat might impede implementation of these results into such
strategy (11,12). Furthermore, despite reticence to con-
uct additional primary prevention studies, the cost of a
egistry might not be very different than that of doing
dditional prospective studies in an attempt to answer the
emaining imponderables.
HE LARGER PERSPECTIVE
t is a general reality that clinical electrophysiology resides
ithin a larger economy of health care, which, in turn, is
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January 3, 2006:108–11 Editorial Commentart of society’s macroeconomy. Although we in the field of
lectrophysiology recognize and passionately support the
linical opportunities of ICD therapy and its important
alue for patient care, such knowledge is diluted in the larger
ool of societal needs, and our views will not prevail with
arginal or uncertain cost benefits. It is necessary that
hysicians, hospitals, and industry, in cooperation with
rganizations that control the flow of research funds, work
oward the common goal of achieving greater efficacy and
ccuracy in ICD indications. Short of this, non-scientific
nfluences will eventually exert control over ICD availability.
hese concerns derive from the experience of the economics
f health care in the 1980s, during a period when the
edical enterprise had warnings about cost escalations that
t did not heed (13,14). As predicted, a disproportionate
hare of the nation’s economic wealth allocated to health
are served as a catalyst for the disastrous health care reform
olicies of the late 1980s and early 1990s. Unfortunately,
ven these reforms did not improve circumstances.
As future technologies emerge, we should take heed of
he lessons learned from the ICD trials. Controllers of the
unding for clinical trials, whether governmental, industrial,
r organizational, must be encouraged to recognize that
uick, less expensive general answers to complex scientific
uestions might look good on one year’s balance sheet, but
ill not likely provide an enduring benefit to patients,
hysicians, or industry, as health care delivery issues become
ore complicated and costly. As we should have learned in
he 1980s, a societal revolution against perceived excesses,
nce started, will be beyond control by any elements of the
edical complex (13). Society’s voice, expressed through
olitical forces, will ultimately prevail.
Will we have an opportunity to respond effectively to the
pecific issue addressed in this overview? We believe so, but
hat is for another discussion.
eprint requests and correspondence: Dr. Robert J. Myerburg,
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